Literature DB >> 20061010

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.

Cristina Teodosio1, Andrés C García-Montero, María Jara-Acevedo, Laura Sánchez-Muñoz, Ivan Alvarez-Twose, Rosa Núñez, Lawrence B Schwartz, Andrew F Walls, Luis Escribano, Alberto Orfao.   

Abstract

BACKGROUND: Systemic mastocytosis (SM) is a heterogeneous group of disorders with distinct clinical and biological behavior. Despite this, little is known about the immunophenotypic features of the distinct diagnostic categories of SM.
OBJECTIVE: To analyze the immunophenotypic characteristics of bone marrow (BM) mast cells (MCs) of different subtypes of SM.
METHODS: Bone marrow samples from 123 patients with different subtypes of SM and 92 controls were analyzed for a broad panel of immunophenotypic markers by flow cytometry.
RESULTS: Three clearly different maturation-associated immunophenotypic profiles were found for BMMCs in SM. These different profiles were associated with both genetic markers of the disease and its clinical behavior. BMMCs from poor-prognosis categories of SM (aggressive SM and MC leukemia) typically showed an immature phenotype with clonal involvement of all myeloid lineages by the D816V stem cell growth factor receptor gene (KIT) mutation. In turn, a mature activated versus resting BMMC immunophenotype was commonly found among patients with good-prognosis subtypes of SM depending on whether they carried (indolent SM and clonal MC activation disorders) or not (well differentiated SM) the D816V KIT mutation.
CONCLUSION: Bone marrow MCs from SM show 3 different maturation-related immunophenotypic profiles that are associated with both the genetic markers of the disease and its clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061010     DOI: 10.1016/j.jaci.2009.10.020

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  34 in total

1.  Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells.

Authors:  A Pardanani; T Lasho; D Chen; T K Kimlinger; C Finke; D Zblewski; M M Patnaik; K K Reichard; E Rowinsky; C A Hanson; C Brooks; A Tefferi
Journal:  Leukemia       Date:  2015-02-02       Impact factor: 11.528

2.  A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Authors:  Jason Gotlib; John H Baird; Tracy I George; Cheryl Langford; Isabel Reyes; Justin Abuel; Cecelia Perkins; Kurt Schroeder; Prithviraj Bose; Srdan Verstovsek
Journal:  Blood Adv       Date:  2019-08-13

3.  Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.

Authors:  Maria Jara-Acevedo; Cristina Teodosio; Laura Sanchez-Muñoz; Ivan Álvarez-Twose; Andrea Mayado; Carolina Caldas; Almudena Matito; José M Morgado; Javier I Muñoz-González; Luis Escribano; Andrés C Garcia-Montero; Alberto Orfao
Journal:  Mod Pathol       Date:  2015-06-12       Impact factor: 7.842

Review 4.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

5.  A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.

Authors:  Melody C Carter; Avanti Desai; Hirsh D Komarow; Yun Bai; Sarah T Clayton; Alicia S Clark; Karina N Ruiz-Esteves; Lauren M Long; Daly Cantave; Todd M Wilson; Linda M Scott; Olga Simakova; Mi-Yeon Jung; Jamie Hahn; Irina Maric; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2017-06-16       Impact factor: 10.793

Review 6.  Invited Commentary: Mast Cell Activation.

Authors:  Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 7.  Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

Review 8.  Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.

Authors:  P Valent; K Sotlar; W R Sperr; L Escribano; S Yavuz; A Reiter; T I George; H C Kluin-Nelemans; O Hermine; J H Butterfield; H Hägglund; C Ustun; J L Hornick; M Triggiani; D Radia; C Akin; K Hartmann; J Gotlib; L B Schwartz; S Verstovsek; A Orfao; D D Metcalfe; M Arock; H-P Horny
Journal:  Ann Oncol       Date:  2014-03-27       Impact factor: 32.976

Review 9.  Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?

Authors:  A Matito; M Carter
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

10.  Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Authors:  Eunice Ching Chan; Yun Bai; Arnold S Kirshenbaum; Elizabeth R Fischer; Olga Simakova; Geethani Bandara; Linda M Scott; Laura B Wisch; Daly Cantave; Melody C Carter; John C Lewis; Pierre Noel; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.